HIGH-GROWTH Diagnostic Testing Markets

SAMPLE COPY, NOT FOR RESALE

Trends, Industry Participants, Product Overviews and Market Drivers
TABLE OF CONTENTS

1. Overview 10
   1.1 Statement of Report 10
   1.2 Scope of This Report 11
   1.3 Methodology 12
   1.4 Executive Summary 13

2. Introduction to the High-Growth Testing Market 24
   2.1 Introduction to the Global Diagnostic Market 24
   2.2 General Areas with Potential for High-Growth Testing 24
   2.3 Market Drivers in the High-Growth Diagnostics Testing Sector 26
   2.4 Market Segments for High-Growth Testing 26
   2.5 Key Players in the High-Growth Diagnostics Testing Segment 26
   2.6 High-Growth Testing Sector Analysis 28

3. Hepatitis Serologic Markers and Nucleic Acid Testing 29
   3.1 Hepatitis B Virus (HBV) 29
   3.2 Major Suppliers of Hepatitis B Virus (HBV) Testing Products 37
   3.3 Market Revenue Analysis 39
   3.4 Hepatitis C Virus (HCV) Testing 40
   3.5 Market Analysis 47
   3.5.1 HCV Market Share 48

4. Human Papillomavirus (HPV) Testing 50
   4.1 Overview 50
   4.2 The Association of HPV and Cervical Cancer 51
   4.3 The PAP Test 52
   4.4 Current Laboratory Methods for HPV Detection 54
   4.4.1 Direct-Probe Methods 54
   4.4.2 Signal Amplification 54
   4.4.3 Target Amplification 54
   4.5 Assays for HPV 55
   4.6 Market Revenue Analysis 62
   4.6.1 North American Market 63
   4.6.2 European Market 66
   4.7 Market and Technology Trends 67
   4.7.1 Market Trends 67
   4.7.2 Technology Trends 68

5. HIV 69
   5.1 Introduction to HIV/AIDS 69
   5.2 Market Dynamics 72
   5.2.1 Market Drivers 72
   5.2.2 Market Restraints 72
   5.2.3 Market Trends 73
   5.2.4 Technology Trends 75
   5.3 Review of Selected HIV Testing Devices 76
   5.3.1 Instruments and MDx Reagents 76
   5.4 Market Analysis 83
   5.5 Competitor Activity 86
   5.6 HIV Market Challenges and Strategic Recommendations 87
   5.7 Insurance Coverage and Reimbursement 89

6. Infectious Disease Testing 90
6.1 Introduction to Infectious Disease Testing 90
6.2 Types of Diagnosis for Infectious Diseases 91
6.2.1 Microbial Culture 91
6.2.2 Microscopy 91
6.2.3 Biochemical Tests 91
6.2.4 Molecular Diagnostics 91
6.3 Diagnostic Platforms for Infectious Diseases 92
6.3.1 Centralized Laboratory Testing for Infectious Diseases 92
6.3.2 POC Testing for Infectious Diseases 92
6.4 Emerging Technologies 93
6.5 Qualitative Analysis 93
6.5.1 Market Drivers 93
6.5.2 Market Restraints 94
6.6 Streptococcus Testing 94
6.7 Chlamydia Testing 97
6.8 Mononucleosis 101
6.9 Gonorrhea 102
6.10 Influenza 107
6.11 Malaria 109
6.12 Tuberculosis 113
6.13 Methicillin-Resistant Staphylococcus Aureus (MRSA) 122
6.14 Market Revenue Analysis 125

7. Cardiac Markers 126
7.1 Market Overview 126
7.2 Cardiac Marker Tests 126
7.2.1 Creatine Kinase (CK) 126
7.2.2 Myoglobin 127
7.2.3 Cardiac Troponins T (TnT), I (TnI) and C (TnC) 127
7.2.4 C-Reactive Protein (CRP) 127
7.2.5 Homocysteine 128
7.3 Emerging Markers 128
7.3.1 B-type Natriuretic Peptide (BNP) 128
7.3.2 Myeloperoxidase (MPO) 129
7.3.3 Ischemia Modified Albumin (IMA) 129
7.3.4 Glycogen Phosphorylase Isoenzyme BB (GPBB) 130
7.3.5 Fatty Acid-Binding Proteins (FABPs) 130
7.4 Qualitative Analysis 131
7.4.1 Market Drivers 131
7.4.2 Market Restraints 133
7.5 Specific Cardiac Conditions 134
7.5.1 Acute Myocardial Infarction 134
7.5.2 Heart Failure (BNP) 134
7.5.2.1 Market Overview 134
7.5.2.2 Commercial Assays for BNP and NT-proBNP 136
7.5.2.3 Clinical Applications of BNP 138
7.5.3 CRP 142
7.6 Pulmonary Embolism (D-dimer Test) 143
7.7 Key Players 143
7.8 Market Revenue Analysis 152

8. Cytogenetic Testing 155
8.1 Cancer Testing 156
8.2 Prenatal Testing and Cytogenetics 158
8.2.1 Cystic Fibrosis Testing 159
8.2.1.1 CF Testing Methodology 161
8.2.1.2 CF Screening Technology Summary 163

9. Cancer Biomarker Testing 164
9.1 Segment Overview 164
9.2 The Cancer Testing Market 165
9.3 Competition 167
9.4 Individual Markets 168
9.4.1 Cancer Pathology: Testing 168
9.4.1.1 Rare Cell/Micro Metastasis Detection 169
9.4.1.2 Cancer Pathology: High-Throughput Screening 169
9.4.1.3 Competition 171
9.4.1.4 Drivers 171
9.4.2 Breast Cancer 172
9.4.2.1 CA 15-3 173
9.4.2.2 CA 27-29 174
9.4.2.3 BRCA1 and BRCA2 Breast and Ovarian Cancer Genes 174
9.4.2.4 Estrogen and Progesterone Receptor (ER and PR) 176
9.4.2.5 Human Epidermal Growth Factor Receptor 2 (HER-2) 178
9.4.2.6 Herceptin 179
9.4.2.7 p53 180
9.4.2.8 MammaPrint 180
9.4.2.9 Drivers for Breast Cancer Test Development 181
9.4.2.9.1 Breast Cancer Molecular Diagnostic Testing Assay Market Trends 181
9.4.2.9.2 Breast Cancer Molecular Diagnostic Testing Assay Technology Trends 181
9.4.2.9.3 Breast Cancer Testing Assay Strategic Recommendations 182
9.4.3 Ovarian Cancer 182
9.4.3.1 Cancer Antigen 125 (CA 125) 183
9.4.3.2 BRCA1 and BRCA2 184
9.4.3.3 Epidermal Growth Factor Receptor (EGFR) 184
9.4.4 Cervical Cancer 185
9.4.4.1 Cervical Cancer Screening Tests 185
9.4.5 Colon Cancer DNA Testing 186
9.5 Pharmacogenomic Cancer Testing 188
9.6 Market Revenue Analysis 191

10. Substance Abuse Testing 193
10.1 Background to POC Substance Abuse Testing 193
10.2 Substance Abuse Test Types 199
10.2.1 Urine Substance/Drug Screening 199
10.2.2 Hair Tests for Substance Abuse and Screening 199
10.2.3 Blood Tests for Substance Abuse and Screening 200
10.2.4 Saliva Tests for Substance Abuse and Screening 200
10.2.5 Sweat Tests for Substance Abuse and Screening 200
10.3 Alcohol Abuse and Screening 200
10.4 Saliva Testing 201
10.5 Qualitative Analysis 201
10.5.1 Market Drivers 201
10.5.2 Market Restraints 202
10.6 Review of Selected POC Substance Abuse Analyzers 202
10.7 Review of Company Products 202
10.7.1 Alere 202
10.7.2 Abbott Diagnostics 202
10.7.3 BioScan Screening Systems, Inc. 202
10.7.4 American Bio Medica Corporation 203

© 2016 TriMark Publications, LLC. All rights reserved.
16. High-Growth Testing Diagnostic Trends 274
16.1 Genetic Testing 274
16.2 Quality Measures 274
16.3 Moderators of Growth 274
16.3.1 Diagnostics and the Aging Population 274
16.3.2 Individualized Medicine 274
16.3.3 Genetic Testing 274
16.4 Workforce Issues 275
16.5 Reimbursement 276
16.5.1 Cardiovascular 276
16.5.2 Screening for Diabetes 277
16.5.3 CPT Test Codes and Payment Amounts 278
16.6 Rapid Near-Patient Testing in Hospitals 280
16.7 Satellite Facilities 280
16.8 Regionalization of Laboratory Care 281
16.9 Requirements for High-Growth Testing 282
16.10 Clinical Laboratory Improvement Act (CLIA) 283

17. Important Technology Trends 286

18. Molecular Diagnostics a Major Diagnostic Technological Advance 289
18.1 Polymerase Chain Reaction (PCR)-Based Molecular Diagnostics 290
18.2 Micrarray Technologies and Molecular Diagnostics 291
18.3 Isothermal Amplification Technologies and Molecular Diagnostics 292
18.4 Miniaturization Technologies and Molecular Diagnostics (Biochips and Lab on a Chip) 292

19. Technology Platform Innovations in POCT 294
19.1 The Biggest New Opportunities in POCT 295
19.2 Latest POCT Technological Platforms 295
19.2.1 Device Miniaturization and Microfluidic Technologies 296
19.2.2 Minimally-Invasive and Non-Invasive POCT Technologies 296
19.2.3 Advances in Wireless Technologies 296
19.2.4 Automation of POCT 296
19.2.5 Developments in New Genomic Technologies (Genotyping, Haplotyping and Sequencing Technologies) 297
19.2.6 Advances in Informatics Technologies 299
19.2.7 Pharmacogenetic Testing 299
19.2.8 Multi Assay Technologies in POCT 300
19.3 Developments in Key Technologies 300
19.3.1 Medical and Biological Sensors and Sensor Systems 300
19.3.2 Recent Biosensor Product Introductions and Latest Innovative Developments 301
19.3.2.1 Nanoscale Sensors for the Detection of Cancer Biomarkers 301
19.3.2.2 ForteBio Introduces Dip and Read Protein G Biosensor for Octet Instruments 302
19.4 Sensor Systems for Diagnostic Applications 303
19.5 Nanogen (The ELITech Group) Third Generation Point of Care Analyzer 305
19.6 Philips Development of Magnotech Technology 305
19.7 Quidel Corporation MChip, AVR Chip and F Chip 306
19.8 Sanofi-Aventis 306

20. Data Management and Connectivity 308
20.1 Wireless LANs 308
20.2 Connectivity Platforms 311
20.2.1 DataLink Data Management System 311
20.2.2 International Technidyne Corporation HEMOCHRON Signature Elite 314
20.2.3 Siemens Diagnostics RAPIDPoint 500
20.2.4 Alere Connect Products
20.2.5 Medical Implant Communications Service (MICS)
20.2.6 Conworx Technology
20.2.7 Alere Informatics
20.2.8 Medasy
20.2.9 NoemaLife
20.3 Advantages of Connectivity
20.3.1 Cost Benefit of POCT and IT Connectivity
20.3.2 Hospital Network Issues
20.4 Analyzer Connectivity Software Solutions

21. Biochips for Clinical Applications
21.1 Breast Cancer DNA Chips

22. Company Profiles
22.1 Abbott Laboratories
22.2 Alere, Inc.
22.3 Beckman Coulter (now part of Danaher)
22.4 Becton, Dickinson and Company
22.5 Biomerica, Inc.
22.6 Bio-Rad Laboratories, Inc.
22.7 Chembio Diagnostics, Inc.
22.8 Hologic Gen Probe
22.9 Johnson & Johnson
22.10 OraSure
22.11 QIAGEN N.V.
22.12 Quidel Corporation
22.13 Roche Diagnostics
22.14 Siemens Healthcare Diagnostics

INDEX OF FIGURES
Figure 1.1: Worldwide Geographic Distribution of Total IVD Testing Market, 2013 and 2018
Figure 1.2: Worldwide Geographic Distribution of Total IVD Testing Markets by Country, 2013
Figure 1.3: Company Market Share for IVD Testing Markets, 2013
Figure 1.4: Geographic Distribution of Chronic HBV Infection
Figure 1.5: Evolution of HBV Markers in Acute and Chronic Infection
Figure 1.6: U.S. Market Share of HCV Molecular Diagnostic Market, 2013
Figure 1.7: Global Market Share (Excluding U.S.) of HCV Molecular Diagnostic Market, 2013
Figure 1.8: Hybrid Capture 2 (HC2) versus PCR—Analytical Sensitivity and Clinical Sensitivity
Figure 1.9: Basic Steps in Hybrid Capture 2 Technology
Figure 1.10: U.S. Market Share of HPV Molecular Diagnostic Market, 2014
Figure 1.11: Global Market Share (Excluding U.S.) of HPV Molecular Diagnostic Market, 2014
Figure 1.12: Market Share Estimates for Molecular Diagnostic HPV Testing, 2014
Figure 1.13: Ten Best Selling AIDS Drugs in the U.S., 2014
Figure 1.14: U.S. Rates for New HIV Cases, 2014
Figure 1.15: U.S. Rates for New HIV Cases in Men, 2014
Figure 1.16: U.S. Rates for New HIV Cases in Women, 2014
Figure 1.17: Estimated Market for Global HIV Molecular Diagnostic Testing, 2011-2020
Figure 1.18: Estimated Market for U.S. HIV Molecular Diagnostic Testing, 2011-2020
Figure 1.19: Market Share Viral Load HIV Molecular Diagnostic Testing
Figure 1.20: U.S. and Outlying Areas Gonorrhea Infection Rates, 1941-2012
Figure 1.21: Mode of Action of Common Malaria RDT Format
IN INDEX OF TABLES

Table 1.1: Emerging Technology Platforms Driving High-Growth Diagnostics Market Segments 13
Table 1.2: Market Trends in the High-Growth Diagnostics Space 15
Table 1.3: Global Distribution of IVD Testing by Key Geographic Regions, 2013 and 2018 18
Table 1.4: Top 15 Country Markets for IVD Testing, 2013 19
Table 1.5: Company Market Share for IVD Testing Markets, 2013 20
Table 1.6: Global Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing, 2008-2018 21
Table 1.7: Global IVD High-Growth Markets Revenues by Market Segment, 2008-2018 21
Table 1.8: Global IVD High-Growth Markets Percentage of Revenues by Geographic Region, 2008-2018 22
Table 1.9: Global IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018 22
Table 3.1: Serological Diagnosis of Hepatitis B Virus Infections 33
Table 3.2: Lower Detection Limits of HBV DNA Assays 34
Table 3.3: Summary of Selected Suppliers of Hepatitis B Virus (HBV) Diagnostic Products by Technology 37
Table 3.4: Global Market for HBV Diagnostic Testing, 2014-2020 39
Table 3.5: U.S. Market for HBV Diagnostic Testing, 2014-2020 39
Table 3.6: Efficiency of Available HCV Screening Tests 44
Table 3.7: Recommendations for Diagnostic Testing for Hepatitis C 45
Table 3.8: U.S. HCV Statistics 45
Table 3.9: Global Market for DNA HCV Diagnostic Testing, 2005-2013 47
Table 3.10: U.S. Market for DNA HCV Diagnostic Testing, 2005-2013 47
Table 3.11: Global Market for NAT HCV Diagnostic Testing, 2014-2020 47
Table 3.12: U.S. Market for NAT HCV Diagnostic Testing, 2014-2020 48
Table 3.13: Major Companies Marketing HCV Molecular Diagnostic Tests: Market Size and Share, 2013 48
Table 4.1: HPV Risk Factors 50
Table 4.2: HPV and Cervical Carcinoma 51
Table 4.3: Number of Pap Smears Performed by Country, 2014 53
Table 4.4: Qiagen’s Digene HC2 High-Risk HPV DNA Test 56
Table 4.5: Commercially Available Molecular Diagnostic Products for HPV Assay 61
Table 4.6: Long-Term Trends in HPV Testing 62
Table 4.7: Major Companies Marketing HPV Molecular Diagnostic Tests: Market Size and Share, 2014 62
Table 4.8: Global Market for HPV Molecular Diagnostic Testing, 2014-2020 67
Table 4.9: U.S. Market for HPV Molecular Diagnostic Testing, 2014-2020 67
Table 5.1: HIV Molecular Diagnostics Market: Market Drivers Ranked in Order of Impact 72
Table 5.2: NAT HIV Monitoring Market: Market Drivers Ranked in Order of Impact 72
Table 5.3: HIV Molecular Diagnostics Market: Market Restraints Ranked in Order of Impact 72
Table 5.4: Drivers of Demand for HIV Diagnostic Testing 73
Table 5.5: NAT HIV Monitoring Market: Market Restraints Ranked in Order of Impact 73
Table 5.6: Summary of Assays for HIV Viral Load Testing 76

© 2016 TriMark Publications, LLC. All rights reserved. www.trimarkpublications.com
| Table 5.7: | Commercially Available Molecular Diagnostic Products for HIV Assay | 82 |
| Table 5.8: | Global Market for Molecular Diagnostic HIV Diagnostic Testing, 2014-2020 | 84 |
| Table 5.9: | U.S. Market for Molecular Diagnostic HIV Diagnostic Testing, 2014-2020 | 84 |
| Table 5.10: | Global Market for HIV Viral Load Diagnostic Testing, 2007-2013 | 85 |
| Table 5.11: | U.S. Market for HIV Viral Load Diagnostic Testing, 2007-2013 | 85 |
| Table 5.12: | Global Market for HIV Viral Load Diagnostic Testing, 2014-2020 | 85 |
| Table 5.13: | U.S. Market for HIV Viral Load Diagnostic Testing, 2014-2020 | 86 |
| Table 5.14: | Competitive Factors Related to HIV Tests | 87 |
| Table 6.1: | Rapid Strep Tests on the Market | 95 |
| Table 6.2: | U.S. Chlamydia Infection Rates, 1985-2012 | 98 |
| Table 6.3: | Rapid Tests for Chlamydia | 99 |
| Table 6.4: | Rapid Tests for Gonorrhea | 104 |
| Table 6.5: | Global Market for Tuberculosis Molecular Diagnostic Testing, 2005-2014 | 122 |
| Table 6.6: | U.S. Market for Tuberculosis Molecular Diagnostic Testing, 2005-2014 | 122 |
| Table 6.7: | Commercially Available Molecular Diagnostic Products for MRSA Assay | 124 |
| Table 6.8: | Global Market for MRSA Diagnostic Testing, 2005-2014 | 125 |
| Table 6.9: | U.S. Market for MRSA Diagnostic Testing, 2005-2014 | 125 |
| Table 7.1: | Medication Chart for Cardiovascular Disease | 131 |
| Table 7.2: | Cardiac Marker Testing Market: Market Drivers Ranked in Order of Impact | 133 |
| Table 7.3: | POC Cardiac Marker Testing Market: Market Restraints Ranked in Order of Impact | 134 |
| Table 7.4: | BNP Clinical Characteristics | 135 |
| Table 7.5: | FDA Approved BNP Assays | 137 |
| Table 7.6: | FDA Approved NT-proBNP Assays | 137 |
| Table 7.7: | BNP Clinical Characteristics | 138 |
| Table 7.8: | Cardiovascular Risk Classification by CRP Level | 142 |
| Table 7.9: | Cardiac Marker Markets by Country and Region, 2010-2020 | 153 |
| Table 7.10: | Cardiac Marker Markets by Country and Region, 2010-2020 | 153 |
| Table 7.11: | Total Global Cardiac Marker Market, 2010-2020 | 153 |
| Table 8.1: | Genetic Testing: Consequences and Challenges | 159 |
| Table 8.2: | CF Carrier Risk by Ethnic Group | 160 |
| Table 8.3: | Reasons for CF Testing | 160 |
| Table 8.4: | CF Gene Detection Rates Vary by Ethnic Background | 162 |
| Table 8.5: | Global Market for CF Diagnostic Testing, 2008-2018 | 162 |
| Table 8.6: | U.S. Market for CF Diagnostic Testing, 2008-2018 | 163 |
| Table 9.1: | Estimates for the Leading Sites of New Cancer Cases in the U.S. by Gender, 2014 | 166 |
| Table 9.2: | Estimates for the Leading Sites of Cancer Deaths in the U.S. by Gender, 2014 | 166 |
| Table 9.3: | Corporate Players Entering the Prostate Cancer Molecular Diagnostic Space | 168 |
| Table 9.4: | Worldwide CA 15-3 Sales, 2009-2019 | 173 |
| Table 9.5: | TPA Marker Sensitivity | 176 |
| Table 9.6: | Overview of ER/PR Testing and Response to Therapy | 177 |
| Table 9.7: | Overview of HER2/neu and Herceptin | 179 |
| Table 9.8: | Breast Cancer Molecular Diagnostic Testing Market: Market Drivers Ranked in Order of Impact 181 |
| Table 9.9: | Commercially Available Molecular Diagnostic Products for Ovarian Cancer Assay | 183 |
| Table 9.10: | INFINITI Applications | 191 |
| Table 9.11: | Global Revenue Forecasts for Cancer Marker Testing, 2008-2018 | 192 |
| Table 10.1: | Stat Urine Testing Drug Recommendations | 198 |
| Table 11.1: | Global Revenue Forecasts for Vitamin D Testing, 2008-2018 | 210 |
| Table 13.1: | Global Distribution of IVD Testing by Key Geographic Regions, 2013 and 2018 | 213 |
| Table 13.2: | Top 15 Country Markets for IVD Testing, 2013 | 216 |
| Table 13.3: | Company Market Share for IVD Testing Markets, 2013 | 217 |
| Table 13.4: | Global Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing, 2008-2018 | 218 |
| Table 13.5: | Global IVD High-Growth Markets Percentage of Revenues by Geographic Region, 2008-2018 | 219 |
| Table 13.6: | Global IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018 | 219 |
| Table 13.7: | Summary of IVD High-Growth Market U.S., 2013 | 220 |
| Table 13.8: | Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing U.S., | 221 |
2008-2018  220
Table 13.9: U.S. Individual IVD High-Growth Markets Revenue Forecast 2008-2018  221
Table 13.10: Cardiac Markers in Clinical Use  222
Table 13.11: Cardiac Markers after Onset of Myocardial Infarction  223
Table 13.12: U.S. Cardiac Marker Market, 2010-2020  225
Table 13.13: U.S. Cardiac Marker Diagnostic Testing Market Segments, 2014  226
Table 13.14: Market Share of Cardiac Marker Segment  227
Table 13.15: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Europe, 2008-2018  229
Table 13.16: Europe: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018  230
Table 13.17: Europe: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018  230
Table 13.18: Cardiac Marker Market for Diagnostic Testing in Europe, 2010-2020  231
Table 13.19: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Brazil, 2008-2018  234
Table 13.20: Brazil: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018  235
Table 13.21: Brazil: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018  235
Table 13.22: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Russia, 2008-2018  237
Table 13.23: Russia: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018  237
Table 13.24: Russia: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018  238
Table 13.25: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing India, 2008-2018  241
Table 13.26: India: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018  241
Table 13.27: India: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018  242
Table 13.28: Disease Burden in China: Urban and Rural  245
Table 13.29: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing China, 2008-2018  251
Table 13.30: China: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018  252
Table 13.31: China: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018  252
Table 13.32: Summary Revenue Forecasts for IVD High-Growth Markets Diagnostic Testing Other Asia, 2008-2018  258
Table 13.33: Other Asia: Individual IVD High-Growth Markets Revenue Forecast, 2008-2018  259
Table 13.34: Other Asia: Individual IVD High-Growth Markets Percentage of Revenues by Product Type, 2008-2018  259
Table 15.1: Medicare National Minimum Payment Amounts for Cervical Pathology Procedures  273
Table 16.1: New CPT Test Codes Introduced in 2008  279
Table 19.1: Common Genotype Techniques  298
Table 20.1: Applications for Wireless LAN Technology  308
Table 20.2: Customized Reports Must Support CAP and JCAHO Requirements  312
Table 20.3: Applications of RALS Connectivity with POCT Devices  313
Table 21.1: Biochip Revenues and Growth Rates by Application, 2012 and 2018  320
Table 21.2: Biochip Revenues and Growth Rates by Type, 2009 and 2015  321
Table 22.1: Drugs of Abuse Cut-off Levels for the TOX  340

© 2016 TriMark Publications, LLC. All rights reserved.
www.trimarkpublications.com
1. Overview

1.1 Statement of Report

The purpose of this report is to describe the specific market segment of the *in vitro* diagnostics market called high-growth diagnostic testing. It examines the clinical measurement devices and their reagents and supplies as utilized in hospitals, clinics and doctor’s offices. Each diagnostic segment described in this report offers an outstanding opportunity for strong market growth over the next five years. Our analysis is arranged to provide the reader with an overview of the outstanding diagnostic test growth market segments that are poised for unusual advances in sales and earnings as the diagnostic market becomes an increasingly important segment of the health delivery system. Each high-growth market segment is accompanied by analysis and forecasts by product type and application.

This analysis provides an overview of the newest growth areas of the diagnostic testing market, including the latest information regarding new products and important industry trends. Forecasts of the market and analyses of products in the worldwide diagnostics market will provide a basis for understanding the significance of new developments and future possibilities within the diagnostic testing segment.

The principal objectives of this review are to:

- Identify key technology drivers through a comprehensive look at various platform technologies for high-growth segments of the diagnostic testing markets.
- Obtain a complete understanding of the chief high-growth diagnostic test predictive, screening, prognostic, monitoring, pharmacogenomic and theranostic value, from their basic principles to their applications.
- Discover feasible market opportunities via an identification of high-growth applications in different diagnostic testing areas, with a focus on the biggest and fastest expanding markets for diseases.
- Focus on global industry development through an in-depth analysis of the major world markets for high-growth diagnostic testing, including forecasts for growth.
- Project and forecast the future of the IVD market. Market figures regarding the current value of the high-growth testing market are taken from the most recent available data of the global diagnostic industry.

This report provides:

- An improved understanding of the current state and future of the most exciting high-growth diagnostic testing market segments.
- The latest information on the leading companies engaged in R&D and diagnostic testing products in the pipeline.
- The analyst’s perspective of recent diagnostic test developments, and revelations on how these influence selected markets.
- Knowledge of the diagnostic testing market as an area of growth, research and investment.

The following categories of diagnostic testing segments are covered herein:

- Hepatitis testing.
- Cardiac monitoring.
- Cytogenetic testing.
- Fertility testing.
- Laboratory genomics.
- Glycosylated hemoglobin and glucose monitoring.
- Cancer marker testing.
- Human papillomavirus (HPV).
- Biochips for clinical applications.
- HIV.
- Cellular imaging cytopathology and histopathology.
- Infectious disease testing.
Analyses include the use of charts and graphs measuring product growth and trends within the marketplace. In addition, a discussion of research in the illness provides the reader with a deeper understanding of possibilities for future diagnosis and avenues for possible research and development budgets. Company-specific information—including product pipeline status, and research and development trends—is provided throughout the report. Additionally, this analysis will:

- Assess the high-growth diagnostic testing market drivers and bottlenecks, from the perspective of the diagnostics industry, as well as medical and scientific communities.
- Discuss the potential benefits provided by the high-growth diagnostic testing market to various sectors of the medical and scientific community.
- Establish the current total market size and future growth of the high-growth diagnostic testing market, and analyze the current size and growth of individual segments.
- Provide current and forecasted market shares by company.
- Discuss business opportunities in the high-growth diagnostic testing segment.
- Provide strategic recommendations for exceptional near-term business opportunities.
- Assess current commercial uses of the high-growth diagnostic testing market.

We answer the following questions in this report:

- What are the near-term business opportunities in the high-growth diagnostic testing market?
- What are the current and forecasted sizes of the high-growth diagnostic testing market?
- What are the business models currently used by companies in the high-growth diagnostic testing market?
- How will diagnostic manufacturers, researchers, physicians, patients and payers influence the high-growth diagnostic testing market?
- What are the drivers and bottlenecks influencing the high-growth diagnostic testing market?
- What are the technologies used in high-growth diagnostic testing?
- Who holds proprietary rights to the high-growth diagnostic testing market technology?
- What are current applications of this technology?
- What regulatory processes must the high-growth diagnostic technologies undergo in the United States, Japan, China and Europe?
- How will new high-growth diagnostic testing technologies change treatment and payment paradigms?
- How will high-growth diagnostic testing technologies reduce adverse drug reactions and decrease total patient care costs?
- How will high-growth diagnostic testing technologies reduce healthcare expenditures?

1.2 Scope of This Report

The emphasis in this review is on those companies that are actively developing and marketing high-growth diagnostic testing technologies. The reader should consult other TriMark Publications reports at www.trimarkpublications.com for a detailed discussion of the important individual market segments which are related to the high-growth diagnostic testing technologies market, such as hepatitis testing, cardiac markers, cancer testing, infectious disease markers and other new diagnostic methods.

This analysis concentrates on high-growth testing market segments in important worldwide markets, such as the U.S., Japan, China and Europe, including Germany, the United Kingdom, and other countries of the European Union (E.U.). It focuses primarily on the hospital market and commercial laboratory segment, and, separately, on a description of the instruments, reagents and supplies marketed by major companies in this segment. The report discusses market size, growth rates, and market components, and five-year projections for each of the important high-growth tests.
1.3 Methodology

The author of this report holds a Ph.D. in biochemistry from the University of Minnesota and has had post-doctoral experience at the University of Connecticut School of Medicine. He has taught at Quinnipiac University and the Tufts School of Medicine, and has been a senior scientist at Pfizer Pharmaceutical Laboratories in drug development. He also has many decades of experience in science writing and as a medical industry analyst. He has over 30 years of experience in laboratory testing and instrument and reagent development technology as a licensed clinical laboratory director, as well as extensive experience in senior level management positions in biotech and medical service companies. The editor of this report is a woman with many decades of experience in science writing and as a medical industry analyst.

Company-specific information is obtained mainly from industry trade publications, academic journals, news and research articles, press releases and corporate websites, as well as annual reports for publicly-held firms. Additional sources of information include non-governmental organizations (NGOs) such as the World Health Organization (WHO) and governmental entities such as the U.S. Department of Health and Human Services (HHS), the National Institutes of Health (NIH), the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Where possible and practicable, the most recent data available have been used.

Some of the statistical information was taken from Biotechnology Associates’ databases and from TriMark’s private data stores. The information in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy, adequacy or completeness of any information or omission or for the results obtained by the use of such information. Key information from the business literature was used as a basis to conduct dialogue with and obtain expert opinion from market professionals regarding commercial potential and market sizes. Senior managers from major company players were interviewed for part of the information in this report.

Primary Sources

TriMark collects information from hundreds of Database Tables and many comprehensive multi-client research projects, as well as Sector Snapshots that it publishes annually. TriMark extracts relevant data and analytics from its research as part of this data collection.

Secondary Sources

TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government-affiliated trade releases and other published information as part of its secondary research materials. The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations.

TriMark Publications Report Research and Data Acquisition Structure

The general sequence of research and analysis activity prior to the publication of every report includes the following items:

- Completing an extensive secondary research effort on an important market sector, including gathering all relevant information from corporate reporting, publicly available databases, proprietary databases, direct meetings and personal interviews with key personnel.
- Formulating a study outline with the assigned writer, including important items:
  - Market and product segment grouping and evaluating their relative significance.
  - Key competitors’ evaluations including their relative positions in the business and other relevant facts to prioritize diligence levels and assist in designing a primary research strategy.
  - End-user research to evaluate analytical significance in market estimation.
- Supply chain research and analysis to identify any factors affecting the market.
- New technology platforms and cutting edge applications.

- Identifying the key technology and market trends that drive or affect these markets. Assessing the regional significance for each product and market segment for proper emphasis of further regional/national primary and secondary research.

- Launching a combination of primary research activities including two levels of questionnaires, executive-direct focused, company-specific, and region-specific communications to qualified and experienced senior executives worldwide.

- Completing a confirmatory primary research assessment of the report’s findings with the assistance of Expert Panel Partners from the industry being analyzed.

1.4 Executive Summary

The high-growth diagnostic products segments are poised for a major new phase of growth fueled by the availability of new technology coming out of the point of care segment, molecular diagnostics and human genome research. There is also a higher awareness of individual patients and general healthcare consumers to take charge of their own health status. Continuous improvements in technology are resulting in a growing number of new in vitro diagnostic tests that combine high levels of accuracy with rapid, easy-to-use product formats. The combination of the new molecular diagnostic technology platforms and traditional PCR will provide customers with a highly sensitive, accurate and rapid solution that is even more robust than either of them alone. These innovative combinations will provide the rich environment for diagnostic tests that grow more than 10% per year in net sales dollars.

Many of the new high-growth in vitro diagnostic products and services are specifically targeted at markets outside of the traditional hospital or clinical laboratory such as the point of care setting or genetic screening. Competition in the development and marketing of high-growth diagnostic products is intense, and diagnostic technologies have been subject to rapid change. We estimate that the competitive factors determining success in the diagnostic market include convenience, privacy, price and product performance as well as the distribution, advertising, promotion and brand name recognition of the marketer.

Table 1.1: Emerging Technology Platforms Driving High-Growth Diagnostics Market Segments

<table>
<thead>
<tr>
<th>Platform</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polymerase Chain Reaction (PCR).</td>
</tr>
<tr>
<td>SYBR Green (Non-probe System).</td>
</tr>
<tr>
<td>MultiCode-RTx System.</td>
</tr>
<tr>
<td>TaqMan” (Probe System).</td>
</tr>
<tr>
<td>HybProbe (Probe System).</td>
</tr>
<tr>
<td>Molecular Beacons (Probe System).</td>
</tr>
<tr>
<td>Branched DNA (bDNA).</td>
</tr>
<tr>
<td>Transcription Mediated Amplification (TMA).</td>
</tr>
<tr>
<td>Invader.</td>
</tr>
<tr>
<td>Signature™</td>
</tr>
<tr>
<td>Other Real-time PCR Instruments.</td>
</tr>
</tbody>
</table>

Source: Biotechnology Associates
Expiration of basic PCR patents in 2005 opened additional opportunities for new diagnostic test markets. Compared to traditional methods, molecular diagnostics offers better performance, shorter testing times and objective results that do not require interpretation by highly-trained technologists. Most of all, clinicians are now able to provide patients and the community with more consistent, affordable and higher-quality healthcare. Expertise in nucleic acid testing (NAT) products and the associated technology platforms has enabled a number of companies to enter this high-growth segment and to obtain U.S. Food and Drug Administration (FDA) approvals for products that detect a wide variety of infectious microorganisms.

TriMark believes that markets will continue to develop for new applications for NAT technology, both in clinical and non-clinical fields. Among clinical fields, we believe NAT technology will be used in new applications, such as genetic predisposition testing and pharmacogenomics, which involves the study of the relationship between nucleic acid sequence variations in an individual’s genome and the individual’s response to a particular drug. We expect that nucleic acid assays will be used in the field of pharmacogenomics to screen patients prior to administering new drugs. Genetic testing to identify individuals at risk of certain diseases and pathological syndromes is emerging as an additional market for NAT technology. Nucleic acid-based testing for SNPs and other genetic anomalies can be used to determine an individual’s predisposition to such conditions as thrombosis or blood clotting.

We see significant opportunities to grow the high-growth diagnostic testing business outside of the U.S. For example, we expect that the enhanced organization will play a critical role in the further commercialization of high-growth diagnostic tests like HPV, tests for cervical cancer screening, urine strip testing in less developed regions, infectious disease testing and hepatitis screening. The high-growth in vitro diagnostic testing market segment is characterized by growth frequently above 10% per year, and occasionally much more. More established testing market segments like hepatitis, HIV or glycohemoglobin are in the former range of growth. Newer segments like laboratory genomics and biochips are in the 30% range of growth, but start from a low base in the $50 million per year range, compared to the nearly $1 billion estimate for more mature testing segments like hepatitis. Other new segments include forensic testing and paternity testing. The major players using the following strategies are pursuing growth in the high-growth sector:

- Improving profit margins through improved product pricing and operational efficiencies.
- Securing a stronger new product pipeline from internal research and development.
- Pursuing licensing and acquisitions opportunities, when financially and strategically attractive.
- Launching diagnostic test business under brand by leveraging marketing and distributing strength in the U.S., maximizing worldwide sales through current and newly identified sales channels in Europe and the rest of world.
- Launching a new and improved CLIA-waived test worldwide.
- Launching rapid diagnostic tests on a worldwide basis in conjunction with a development partner such as a pharmaceutical company.
- Expanding development and marketing collaborations with large pharmaceutical and other healthcare companies.
- Identifying business development opportunities in the form of product or company acquisitions to enhance product portfolio and further leverage distribution channels worldwide.
- Expanding international sales through external alliances, collaborations and sales focus.

TriMark believes that significant market potential exists for rapid diagnostics with novel applications that are capable of precise quantitative measurement of single or multiple analytes. Rapid, point of care testing is optimal to significantly improve patient care and reduce healthcare costs, especially for acute conditions. However, diagnostic needs and objectives vary from hospital to hospital. Therefore, most diagnostic reagent manufacturers have made their tests available on a centralized automated testing platform in addition to their own existing technology platforms.
### Table 1.2: Market Trends in the High-Growth Diagnostics Space

- Tests based upon molecular diagnostic (nucleic acid) technology platforms.
- Move toward marketing rapid point of care test kits.
- Tests developed as CLIA-waived tests.
- Cost per test less of an issue with high demand diagnostic tests.
- Coupling the diagnostic test with high profile diseases, *e.g.*, ovarian or breast cancer.
- Move toward bringing complicated tests into a single expert lab.
- Move for CLIA regulatory oversight using expert labs, rather than FDA using diagnostic kits.
- Move away from central lab “big iron” chemistry analyzers.
- Focus on improving patient outcomes with diagnostic tests.
- Move to reduce expertise needed to run tests because of shortage of trained personnel.
- More diagnostic start-ups to develop tests with high growth potential.
- Increased M&As as larger players acquire exciting new test technology.

**Source:** Biotechnology Associates

Rapid identification of biological agents is critical to national defense, for example, the application of technology to the detection of biological agents in the water supply. There is currently a need for optimizing a platform for specific use as a field-deployable system to enable biodefense first responders, such as fire and police departments, to rapidly and more accurately detect signature nucleic acid sequences of known biological pathogens (*e.g.*, anthrax and plague). Public attention to agricultural biotechnology continues to grow. Several companies are developing a diagnostic tool to detect genetically modified organisms (GMOs) and address the need to rapidly identify biologic contamination. Approximately $6.5 billion was spent on genomic and proteomic research in 2015, and this figure is projected to grow by at least 20% each year for the next five years. The underlying technology must be applicable to both disease and population-driven genomics and are best developed through corporate partnerships.

The demand for the latest tests and technology is expanding. More and more hospital labs are consolidating and seeking to expand their test menus, and to keep more tests on-site. At the same time, larger independent reference labs like Quest Diagnostics and LabCorp are seeking to stay on the cutting edge of esoteric testing and are making major investments in research and development to keep pace. We have selected 12 test categories that we believe constitute most of the total high-growth *in vitro* diagnostic testing market:

- Hepatitis testing.
- Cardiac markers.
- Cytogenetic testing.
- Fertility testing.
- Genomics testing.
- Glycosylated hemoglobin and glucose monitoring.
- Cancer testing.
- HPV.
- Biochips for clinical applications.
- HIV.
- Cellular imaging.
- Infectious disease testing.